Skip to main navigation

Contact Us
Global
- International
- Canada
- France
- Germany
- Italy
- Japan
- Netherlands
- Spain

About Amicus
- About Amicus
- Belief Statement
- Board of Directors
- Our Founding Legacy
- Senior Management Team
- Message from the President and CEO
Patient Advocacy
- Patient Advocacy
- Rare Stories
- Patient Advisory Boards
- Resources
- Expanded Access
Programs & Pipeline
- Programs & Pipeline
- Our Pipeline
- Fabry Disease
- Pompe Disease
- Batten Disease
- Additional Preclinical Programs
- Clinical Trials
- Global Research Center
Products
- Products & Services
- Galafold^®(migalastat)
- Pombiliti^® + Opfolda^®(cipaglucosidase alfa-atga) (miglustat)
- AMICUS ASSIST^®
Responsibility
- Responsibility
- Ethics & Compliance
- Global Medical Affairs
- Corporate Giving
- Healing Beyond Disease
- ESG Report
Investors & Media
- Investors & Media
- Investor Relations
- Corporate Governance
- Press Releases
- Events & Presentations
- Annual Reports and Proxies
- SEC Filings
- Stock Performance
- Analyst Consensus
- Investor FAQs
- Contact Us
- Sign Up for Email Alerts
Careers
- Careers
- Overview
- Search

Investors

Press Releases

Press Releases

Year

June 4, 2024

Amicus Therapeutics Receives Prix Galien U.K. Award for Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) as Best Pharmaceutical Product

May 9, 2024

Amicus Therapeutics Announces First Quarter 2024 Financial Results and Corporate Updates

May 8, 2024

Amicus Therapeutics to Present at the Bank of America 2024 Health Care Conference

May 1, 2024

Amicus Therapeutics to Announce First Quarter 2024 Financial Results on May 9, 2024

March 20, 2024

Amicus Therapeutics Issues 2024 Environmental, Social, and Governance (ESG) Report

March 1, 2024

Amicus Therapeutics to Present at Upcoming Investor Conferences in March 2024

February 28, 2024

Amicus Therapeutics Announces Full-Year 2023 Financial Results and Corporate Updates

February 15, 2024

Amicus Therapeutics to Announce Full Year 2023 Financial Results on February 28, 2024

February 8, 2024

Amicus Therapeutics Receives the 2024 New Treatment Award for Pombiliti™ (cipaglucosidase alfa-atga) + Opfolda™ (miglustat) at the 20th Annual WORLDSymposium™

February 1, 2024

Amicus Therapeutics Announces Presentations and Posters at the 20th Annual WORLDSymposium™ 2024

Pagination

First page
Previous page
Page 1
Current page 2
Page 3
Next page
Last page

About Amicus

Patient Advocacy

Programs & Pipeline

Our Products

Responsibility

Investors & Media

Careers

Social Media
- Twitter
- YouTube
- LinkedIn

Copyright © 2024 Amicus Therapeutics. All rights reserved. NP-AT-ALL-00011119

Cookies Statement
Terms of Use
Privacy Notice
Privacy Shield Policy

The site you are about to enter is intended for US healthcare professionals.

Please confirm you are a US healthcare professional.

I am a US healthcare professional I am not a US healthcare professional